Immuneering Corporation (IMRX) Research

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.

Market snapshot

Symbol
IMRX
Price
$4.41
Day change
+0.00%
Market cap
$160.1M
P/E ratio
-3.57x
52-week range
2.29-10.08
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$12.00

Peer companies

  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Assembly Biosciences, Inc. (ASMB)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Foghorn Therapeutics Inc. (FHTX)
  • Humacyte, Inc. (HUMA)
  • Nautilus Biotechnology, Inc. (NAUT)
  • Pyxis Oncology, Inc. (PYXS)
  • Tenaya Therapeutics, Inc. (TNYA)

Recent insider activity

  • Hall Brett Matthew — P-Purchase (6035 shares) on 2026-06-15
  • Schall Thomas J. — A-Award (33350 shares) on 2026-06-11
  • HAUSMAN DIANA — A-Award (33350 shares) on 2026-06-11
  • CARPENTER ROBERT J — A-Award (33350 shares) on 2026-06-11
  • KEATING LAURIE — A-Award (33350 shares) on 2026-06-11

Open Immuneering Corporation (IMRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.